research 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)
Finasteride increases risk of sleep apnea and insomnia.
Search
for
Sort by
Research
90-120 / 1000+ results 
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research AB0697 COMPARISON OF COVID-19 VACCINATION WITH INFLUENZA VACCINATION IN KOREAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PERCEPTION, ADVERSE EVENTS, AND FLARES FROM THE CIVIL STUDY
COVID-19 vaccines had more side effects and worse perception than flu vaccines in Korean lupus patients.
research Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
research Laser-Assisted Exosome Delivery (LAED) with Fractional CO2 Laser: A Pilot Two-Case Report and Narrative Review
Laser-Assisted Exosome Delivery showed early skin improvement without side effects, but more research is needed.
research Budesonide for maintenance of remission in Crohn's disease
Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
research The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy
Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
research Sex- or Gender-specific Differences in the Clinical Presentation, Outcome, and Treatment of SARS-CoV-2
Men face more severe COVID-19 outcomes, while women are more likely to have long-term symptoms.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Olink proteomics analysis of scalp psoriasis reveals a cytokine storm inflammatory mainly related to bacterial-derived antigens
Scalp psoriasis inflammation is mainly caused by bacteria-related triggers.
research Children and Adolescents with Alopecia Areata: Psychiatric Symptomatology and Life Events: A longitudinal case-control study: Before and During the COVID-19
Children with alopecia areata often face more stress and depression, especially related to separation, which can affect their condition.
research A case of alopecia areata after rabies vaccination: unreported adverse effect?
Rabies vaccine might cause hair loss due to immune issues.
research The impact of human immunodeficiency virus-related diseases on pigmented skin types
HIV can cause skin disorders, which are often the first sign of infection, especially in people with darker skin.
research 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Attenuates the Adverse Effects of Glucocorticoids on Dermal Papilla Cells
Blocking 11β-HSD1 can lessen the harmful effects of glucocorticoids on hair growth cells.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
Skin side effects from cancer treatments can lead to changes in therapy and are common, with nail changes being the most frequent.
research Dermatologic Care of the Transplant Patient
Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.
research Identification and characterization of four immune-related signatures in keloid
Four specific genes are linked to keloid formation and could be potential treatment targets.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
Methimazole for hyperthyroidism has known and new side effects needing more study for safety.
research Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.
research Minoxidil for patchy alopecia areata: systematic review and meta‐analysis
Minoxidil effectively and safely treats patchy hair loss, but more research needed.
research Tapinarof cream for atopic dermatitis: Pharmacokinetics, systemic exposure, and preliminary efficacy/safety results
Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
research Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers
Taking five small dutasteride capsules is the same as taking one larger capsule.
research Treatments for alopecia areata: a network meta-analysis
The analysis aims to identify the most effective and safest treatments for alopecia areata.